Pathogenesis

References

21. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, Monaco J, Ehler L, Mizell S, Jackson R, Li Y, Romano JW & Fauci AS (1998). Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. Journal of Clinical Investigation, 102: 223-231.
22. Umehara F, Izumo S, Takeya M, Takahashi K, Sato E & Osame M (1996). Expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy. Acta Neuropathologica, 91: 343-350.
23. Giraudon P, Buart S, Bernard A & Belin MF (1997). Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Molecular Psychiatry, 2: 107-110.
24. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S & Schneck JP (1998). Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from TSP/HAM patients. Proceedings of the National Academy of Sciences, USA, 95: 7568-7573.
25. Biddison WE, Kubota R, Kawanishi T, Taub DD, Cruikshank WW, Center DM, Connor EW, Utz U & Jacobson S (1997). Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. Journal of Immunology, 159: 2018-2025.
26. Hoffman PM, Dhib-Jalbut S, Mikovits JA, Robbins DS, Wolf AL, Bergey GK, Lohrey NC, Weislow OS & Ruscetti FW (1992). Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. Proceedings of the National Academy of Sciences, USA, 89: 11784-11788.
27. Fox RJ, Levin MC & Jacobson S (1996). Tumor necrosis factor alpha expression in the spinal cord of human T-cell lymphotrophic virus type I associated myelopathy/tropical spastic paraparesis patients. Journal of Neurovirology, 2: 323-329.
28. Nagai M, Ijichi S, Hall WW & Osame M (1995). Differential effect of TGF-beta 1 on the in vitro activation of HTLV-I and the proliferative response of CD8+ T lymphocytes in patients with HTLV-I-associated myelopathy (TSP/HAM). Clinical Immunology and Immunopathology, 77: 324-331.
29. Saarloos MN, Koenig RE & Spear GT (1995). Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis. Journal of Infectious Diseases, 172: 1095-1097.
30. Lira J, Nakamura M, Sawada Y, Ohori N, Itoyama Y, Yamamoto N, Sakaki Y & Goto I (1992). Antibody titers to HTLV-Ip40tax protein and gag-env hybrid protein in HTLV-I-asscoiated myelopathy/tropical spastic paraparesis: correlation with increased HTLV-I proviral DNA load. Journal of Neurological Sciences, 107: 98-104.
31. Usuku K, Sonoda S, Osame M, Yashiki S, Takahashi K, Matsumoto M, Sawada T, Tsuji K, Tara M & Igata A (1988). HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Annals of Neurology, 23: 143-150.
32. Godoy AJ, Itoyama Y, Tokunaga K, Hara H, Kawaga Y, Kiyokawa H, Maeda Y & Goto I (1994). Allolymphocytotoxic antibodies in sera from HTLV-I-associated myelopathy/tropical spastic paraparesis patients-putative anti-HLA antibodies. Journal of Neurological Sciences, 125: 62-69.
33. Uchiyama T (1997). Human T cell leukemia virus type I (HTLV-I) and human diseases. Annual Review of Immunology, 15: 15-37.
34. Manns A, Hanchard B, Morgan OS, Wilks R, Cranston B, Nam JM, Blank M, Kuwayama M, Yashiki S, Fujiyoshi T, Blattner W & Sonoda S (1998). Human leukocyte antigen class II alleles associated with human T-cell lymphotropic virus type I infection and adult T-cell leukemia/lymphoma in a Black population. Journal of the National Cancer Institute, 90: 617-622.
35. Jeffery KJM, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, Lloyd AL, Nowak MA, Nagai M, Kodama D, Izumo S, Osame M & Bangham CRM (1999). HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proceedings of the National Academy of Sciences, USA, 96: 3848-3853.
36. Bangham CRM, Kermode AL, Hall SE & Daenke S (1996). The cytotoxic T-lymphocyte response to HTLV-I: the main determinant of disease? Seminars in Virology, 7: 41-48.
37. Höllsberg P (1997). Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Acta Neurologica Scandinavica, 169 (Suppl): 86-93.
38. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T & Jacobson S (1993). High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. Journal of Experimental Medicine, 177: 1567-1573.
39. Casseb J, Hong MA, Salomão S, Duarte AJS, Gallo D & Hendry RM (1997). Coinfection with human immunodeficiency virus and human T-cell lymphotropic virus type I: Reciprocal activation with clinical and immunological consequences. Clinical Infectious Diseases, 25: 1259-1260.
40. Casseb J (1998). Is HTLV-I more clever than HIV-1? Clinical Infectious Diseases, 27: 1309-1310.

Table 1 - Characteristics of tropical spastic paraparesis/human T-cell leukemia type 1-associated mielopatia (TSP/HAM) and adult T-cell leukemia (ATL).

Figure 1 - Modelo for the pathogenesis of tropical spastic paraparesis/HTLV-I-associated mielopatia. CTL, Cytotoxic T lymphocyte; NK, natural killer cell; MF, macrophage.